U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07249073) titled 'CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma' on July 31.
Brief Summary: 1. Objective to evaluate the safety and tolerability of CAR19-BCMA dual-target CAR-T in the treatment of relapsed / refractory multiple myeloma.
2. To determine the maximum tolerated dose (MTD) of car19-bcma dual target car-t in the treatment of relapsed / refractory multiple myeloma.
Study Start Date: March 28
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: CAR19-BCMA dual-target CAR-T
This drug is CAR-T cell injection. CAR-T cells are based on the traditional CAR-T treatment, using ...